Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Obesity Pipeline Overview Number of Assets by Phase Certain mature disease areas have many different commercialized therapeutic drug choices to meet myriad patient requirements, yet the obesity space is at a relatively early stage of development and served by a narrow set of therapeutic options
The versatility of GLP1 in addressing various metabolic disorders highlights its importance in modern medicine and underscores the need for continued research to fully unlock its therapeutic potential
However, current and next-gen obesity therapeutics have the potential to vastly improve health outcomes
This page compiles the current prescribing data and what the clinical trials actually show
This is one of the biggest purchases of a power company in U.S
These improvements reduce the burden associated with frequent injections and make GLP-1 therapies more accessible to a broader population, such as those who may be hesitant about injectable medications
US$ 23.86
US$ 29.49
US$ 22.62
US$ 21.75
US$ 23.30
US$ 24.61
US$ 22.80
US$ 22.77
US$ 28.71
US$ 27.82
US$ 22.00
US$ 27.09
US$ 24.69
US$ 22.58
US$ 22.70
US$ 28.73
